Loading patent…
AssigneesUniversity of Maryland, College Park, Danmarks Tekniske Universitet, The Regents of the University of California
InventorsThomas R. Fuerst, Eric A. Toth, Nathan Lewis, Bjorn Gunnar Voldborg, Wan Tien Chiang
Estimating the term…
Disclosed herein are methods of producing glyco-modified viral antigens that provide a shift of the glycosylation profile of recombinant produced viral antigens (e.g. glycoproteins) towards the naturally occurring viral antigens (e.g. glycoproteins). Disclosed are methods of producing a modified viral antigen comprising expressing a viral antigen in a recombinant mammalian cell line having one or more of the endogenous genes Mgat2, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, B4galt1, B4galt2, B4galt3, B4galt4, B4galt5, B3gnt2, St3Gal6, SPPL3, and/or FUT8 inactivated and/or downregulated; and optionally a gene ST6Gall inserted. Disclosed are glyco-modified viral antigens produced by the method of using a recombinant mammalian cell line. Disclosed are methods of treating a subject in need thereof comprising administering a composition comprising a therapeutically effective amount of one or more of the glyco-modified viral antigens. Disclosed are methods of screening for an antibody specific to one or more of the disclosed glyco-modified viral antigens.
A method of producing a glyco-modified viral antigen comprising:
The method of any of the preceding claims, wherein the glyco-modified viral antigen has increased antigenicity compared to the viral antigen.
The method any of the preceding claims, wherein the glyco-modified viral antigen comprises one or more of the glycan structures:
A glyco-modified viral antigen produced by the method of any of the preceding claims.
A glyco-modified hepatitis C virus (HCV) E2 glycoprotein comprising an antigenic domain D, wherein the modified hepatitis C virus (HCV) E2 glycoprotein comprises one or more amino acid alterations in the antigenic domain D and further comprising one or more of the glycan structures of Table 1.
A glyco-modified membrane bound hepatitis C virus (HCV) E1E2 glycoprotein comprising an HCV E1 glycoprotein and a modified HCV E2 glycoprotein, wherein the modified HCV E2 glycoprotein comprises an antigenic domain D, wherein the modified HCV E2 glycoproteins comprise one or more amino acid alterations in the antigenic domain D and further comprising one or more of the glycan structures of Table 1.
A glyco-modified hepatitis C virus (HCV) E1E2 glycoprotein comprising:
Dependencies are inferred from the claim text.